Please provide your email address to receive an email when new articles are posted on . The addition of blinatumomab to chemotherapy improved DFS for children with B-cell ALL. Researchers stopped ...

In the phase III ECOG-ACRIN E1910 study presented at the American Society of Hematology (ASH) annual meeting, consolidation chemotherapy with blinatumomab (Blincyto) improved overall survival in ...

Doctors have found a gentler treatment for children whose leukaemia has come back, which could boost survival and quality of ...

A gentler treatment for children whose leukemia has come back could boost survival and quality of life, a study led by a UCL academic has found.

Discover comprehensive details about Blinatumomab, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Blinatumomab addition to chemotherapy significantly improves survival and reduces relapse in pediatric B-cell acute lymphoblastic leukemia, especially in high-risk groups. The trial demonstrated that ...

The lead investigator of the study from the Children's Oncology Group said the findings represent a new standard of care. Children with a first relapse of B-cell acute lymphoblastic leukemia (B-ALL) ...

Please provide your email address to receive an email when new articles are posted on . Results of two studies published in JAMA showed the addition of blinatumomab to consolidation chemotherapy ...

A study presented at the American Society of Hematology annual meeting identified TCL1A as a potential predictive biomarker for blinatumomab (Blincyto) response in relapsed pediatric B-cell acute ...

The appraisal committee reviewed the data available on the clinical and cost effectiveness of blinatumomab, having considered evidence on the nature of acute lymphoblastic leukaemia and the value ...

Response criteria for each study are provided in Supplementary Table S1. Patients who achieved a remission within the first two cycles could receive up to three additional cycles of blinatumomab or ...